Nancy Reau to Hepatitis C
This is a "connection" page, showing publications Nancy Reau has written about Hepatitis C.
Connection Strength
7.282
-
Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States. Clin Infect Dis. 2022 Aug 24; 75(1):e955-e961.
Score: 0.822
-
Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. Adv Ther. 2021 12; 38(12):5777-5790.
Score: 0.776
-
Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis?C. Adv Ther. 2021 01; 38(1):423-440.
Score: 0.725
-
Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. J Gen Intern Med. 2020 04; 35(4):1011-1020.
Score: 0.676
-
Report from the International Conference on Viral Hepatitis - 2017. AIDS Rev. 2018 Jan-Mar; 20(1):58-70.
Score: 0.596
-
HBV reactivation after HCV eradication: Deja Vu. Liver Int. 2017 07; 37(7):1088.
Score: 0.575
-
Generic medications for hepatitis C. Liver Int. 2016 07; 36(7):925-8.
Score: 0.537
-
Naives, nonresponders, relapsers: who is there left to treat? Clin Liver Dis. 2011 Aug; 15(3):483-95.
Score: 0.382
-
Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011 Mar; 106(3):452-8.
Score: 0.363
-
Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008 Aug; 103(8):1981-8.
Score: 0.310
-
Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States. Clin Infect Dis. 2021 11 02; 73(9):e3355-e3357.
Score: 0.194
-
Willingness to participate in research among black patients with liver disease: A national cross-sectional study. J Viral Hepat. 2021 07; 28(7):982-993.
Score: 0.187
-
Patient-reported outcomes 12?months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. Liver Int. 2021 04; 41(4):692-704.
Score: 0.184
-
Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. Curr Med Res Opin. 2020 08; 36(8):1325-1332.
Score: 0.177
-
Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS?CO13 HEPAVIH)". J Hepatol. 2020 03; 72(3):592-593.
Score: 0.171
-
Liver Diseases During Pregnancy. Clin Liver Dis. 2019 05; 23(2):345-361.
Score: 0.161
-
ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol. 2016 Feb; 111(2):176-94; quiz 196.
Score: 0.130
-
Preparing for the uncertain yet inevitable: off-label combinations of antiviral agents in hepatitis C virus. Hepatology. 2014 May; 59(5):1688-91.
Score: 0.114
-
Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant. 2012 Nov-Dec; 26(6):826-32.
Score: 0.101
-
Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol. 2012 Jun; 56(6):1276-82.
Score: 0.099